Edesa Historical Balance Sheet
EDSA Stock | USD 4.47 0.10 2.19% |
Trend analysis of Edesa Biotech balance sheet accounts such as Total Current Liabilities of 1.3 M or Total Stockholder Equity of 6.4 M provides information on Edesa Biotech's total assets, liabilities, and equity, which is the actual value of Edesa Biotech to its prevalent stockholders. By breaking down trends over time using Edesa Biotech balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Financial Statement Analysis is much more than just reviewing and examining Edesa Biotech latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Edesa Biotech is a good buy for the upcoming year.
Edesa Biotech Inventory |
|
Edesa |
About Edesa Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of Edesa Biotech at a specified time, usually calculated after every quarter, six months, or one year. Edesa Biotech Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Edesa Biotech and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Edesa currently owns. An asset can also be divided into two categories, current and non-current.
Edesa Biotech Balance Sheet Chart
Edesa Biotech Balance Sheet is one of the main financial statements that report all assets, liabilities, and shareholders' equity for the current year. It provides a basis for different types of computing rates of return, such as return on equity (ROE) or return on asset (ROA), as well as shows how Edesa Biotech uses and utilizes its capital. It also shows what exactly a company owns and owes.
At present, Edesa Biotech's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 209.5 K, whereas Total Assets are forecasted to decline to about 8.7 M. Add Fundamental
Total Assets
Total assets refers to the total amount of Edesa Biotech assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Edesa Biotech books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Total Current Liabilities
Total Current Liabilities is an item on Edesa Biotech balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Edesa Biotech are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Non Current Assets Total
The total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets.Most accounts from Edesa Biotech's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Edesa Biotech current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Edesa Biotech. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. For information on how to trade Edesa Stock refer to our How to Trade Edesa Stock guide.At present, Edesa Biotech's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 209.5 K, whereas Total Assets are forecasted to decline to about 8.7 M.
2021 | 2022 | 2023 | 2024 (projected) | Other Current Liabilities | 2.1M | 1.7M | 2.0M | 1.2M | Total Assets | 11.6M | 8.9M | 10.2M | 8.7M |
Edesa Biotech balance sheet Correlations
Click cells to compare fundamentals
Edesa Biotech Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Edesa Biotech balance sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 10.8M | 14.6M | 11.6M | 8.9M | 10.2M | 8.7M | |
Other Current Liab | 1.5M | 1.4M | 2.1M | 1.7M | 2.0M | 1.2M | |
Total Current Liabilities | 1.5M | 1.5M | 2.1M | 1.8M | 2.1M | 1.3M | |
Total Stockholder Equity | 6.6M | 13.1M | 9.4M | 7.0M | 8.1M | 6.4M | |
Net Debt | (7.0M) | (7.7M) | (7.1M) | (5.3M) | (4.7M) | (5.0M) | |
Retained Earnings | (13.1M) | (26.5M) | (44.0M) | (52.4M) | (47.2M) | (44.8M) | |
Cash | 7.2M | 7.8M | 7.1M | 5.4M | 6.2M | 5.6M | |
Non Current Assets Total | 2.7M | 2.5M | 2.5M | 2.5M | 2.8M | 3.0M | |
Cash And Short Term Investments | 7.2M | 7.8M | 7.1M | 5.4M | 6.2M | 6.8M | |
Common Stock Shares Outstanding | 1.2M | 1.7M | 2.1M | 2.9M | 3.3M | 3.5M | |
Liabilities And Stockholders Equity | 10.8M | 14.6M | 11.6M | 8.9M | 10.2M | 8.7M | |
Other Current Assets | 890.3K | 948.6K | 2.0M | 448.9K | 516.2K | 429.9K | |
Other Stockholder Equity | 1.3M | 4.7M | 11.2M | 13.0M | 15.0M | 15.7M | |
Total Liab | 4.1M | 1.5M | 2.2M | 1.8M | 2.1M | 2.3M | |
Total Current Assets | 8.1M | 12.1M | 9.1M | 6.4M | 7.4M | 7.6M | |
Property Plant And Equipment Net | 174.8K | 111.6K | 31.2K | 100.1K | 90.1K | 85.6K | |
Net Receivables | 87.4K | 3.3M | 1.3M | 626.5K | 720.5K | 521.2K | |
Property Plant And Equipment Gross | 174.8K | 145.4K | 70.7K | 143.9K | 129.5K | 123.1K | |
Accumulated Other Comprehensive Income | (287.2K) | (205.3K) | (213.6K) | (214.6K) | (246.8K) | (234.5K) | |
Non Current Liabilities Total | 2.6M | 67.7K | 43.7K | 19.8K | 17.8K | 16.9K | |
Inventory | 224.3K | (217.1K) | (87.4K) | (1.3M) | (1.1M) | (1.1M) | |
Common Stock | 18.5M | 34.9M | 42.5M | 46.6M | 53.6M | 39.4M | |
Property Plant Equipment | 73.1K | 174.8K | 111.6K | 31.2K | 28.0K | 26.6K | |
Accounts Payable | 1.5M | 1.4M | 2.1M | 1.7K | 2.0K | 1.9K | |
Net Tangible Assets | 5.3M | 4.1M | 10.7M | 7.1M | 8.2M | 4.3M | |
Net Invested Capital | 6.6M | 13.1M | 9.4M | 7.0M | 8.1M | 9.4M | |
Net Working Capital | 6.6M | 10.6M | 7.0M | 4.6M | 4.2M | 5.8M | |
Capital Stock | 18.5M | 34.9M | 42.5M | 46.6M | 53.6M | 38.7M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.MSFT | Microsoft | |
GM | General Motors | |
CRM | Salesforce |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Edesa Biotech. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state. For information on how to trade Edesa Stock refer to our How to Trade Edesa Stock guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for Edesa Stock analysis
When running Edesa Biotech's price analysis, check to measure Edesa Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edesa Biotech is operating at the current time. Most of Edesa Biotech's value examination focuses on studying past and present price action to predict the probability of Edesa Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Edesa Biotech's price. Additionally, you may evaluate how the addition of Edesa Biotech to your portfolios can decrease your overall portfolio volatility.
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |
Is Edesa Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Edesa Biotech. If investors know Edesa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Edesa Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (20.16) | Quarterly Revenue Growth (1.00) | Return On Assets (0.56) | Return On Equity (0.96) |
The market value of Edesa Biotech is measured differently than its book value, which is the value of Edesa that is recorded on the company's balance sheet. Investors also form their own opinion of Edesa Biotech's value that differs from its market value or its book value, called intrinsic value, which is Edesa Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Edesa Biotech's market value can be influenced by many factors that don't directly affect Edesa Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Edesa Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Edesa Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Edesa Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.